» Articles » PMID: 21078797

The Value of 99mTc-tetrofosmin Brain SPECT in Predicting Survival in Patients with Glioblastoma Multiforme

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2010 Nov 17
PMID 21078797
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: (99m)Tc-tetrofosmin brain SPECT has been reported as a useful tool for the evaluation of glioma proliferation. In the present study, we set out to investigate the prognostic value of (99m)Tc-tetrofosmin brain SPECT in patients with glioblastoma multiforme.

Methods: We prospectively studied 18 patients (13 men, 5 women; mean age ± SD, 60.8 ± 7.79 y) who were operated on for glioblastoma multiforme. All patients underwent preoperative (99m)Tc-tetrofosmin brain SPECT, and surgical excision was performed within a week after SPECT. All patients received postoperative radiotherapy and chemotherapy.

Results: By calculating the lesion-to-normal (L/N) (99m)Tc-tetrofosmin uptake ratio, we found that patients with an L/N ratio of more than 4.7 had significantly worse survival than did patients with an L/N ratio of 4.7 or less. Furthermore, patients with a Karnofsky Performance Score more than 90 had a significantly better survival rate. Although patients with near-total tumor resection who were younger than 60 y survived longer, the difference did not reach statistical significance. In the multivariate analysis, (99m)Tc-tetrofosmin uptake and Karnofsky Performance Score were identified as factors with independent prognostic power.

Conclusion: (99m)Tc-tetrofosmin brain SPECT may be an independent prognostic factor in patients with glioblastoma multiforme. Further larger studies are needed to verify these results.

Citing Articles

Nuclear Medicine and Cancer Theragnostics: Basic Concepts.

Zoi V, Giannakopoulou M, Alexiou G, Bouziotis P, Thalasselis S, Tzakos A Diagnostics (Basel). 2023; 13(19).

PMID: 37835806 PMC: 10572920. DOI: 10.3390/diagnostics13193064.


Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma.

Aravantinou-Fatorou A, Georgakopoulou V, Mathioudakis N, Papalexis P, Tarantinos K, Trakas I Mol Clin Oncol. 2023; 19(3):73.

PMID: 37614373 PMC: 10442729. DOI: 10.3892/mco.2023.2669.


Comparison of (99m)tc-tetrofosmin and (99m)tc-sestamibi uptake in glioma cell lines: the role of p-glycoprotein expression.

Alexiou G, Xourgia X, Vartholomatos E, Tsiouris S, Kalef-Ezra J, Fotopoulos A Int J Mol Imaging. 2014; 2014:471032.

PMID: 25436147 PMC: 4243134. DOI: 10.1155/2014/471032.


Pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT: does it have a place in predicting survival in patients with glioblastoma multiforme?.

Amin A, Mustafa M, Abd El-Hadi E, Monier A, Badwey A, Saad E J Neurooncol. 2014; 121(2):303-9.

PMID: 25349131 DOI: 10.1007/s11060-014-1633-9.


Is there a Role for Spect with (99m)Tc-Tetrofosmin in the Diagnostic Work Up of a Brain Tumor?.

Birbilis T, Boussios N, Papatheodossiou L, Matis G, Zissimopoulos A Maedica (Bucur). 2014; 8(4):347-50.

PMID: 24790666 PMC: 3968470.